-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Arrowhead Pharma, Raises Price Target to $80

Benzinga·12/11/2025 15:19:10
語音播報
RBC Capital analyst Luca Issi maintains Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and raises the price target from $52 to $80.